5 takeaways from AP's report on the big backlog of uninspected drug factories
Nearly five years after COVID-19, a new analysis by The Associated Press shows that U.S. regulators are struggling to address a massive backlog of uninspected pharmaceutical plants
Nearly five years after COVID-19, a new analysis by The Associated Press shows that U.S. regulators are struggling to address a massive backlog of uninspected pharmaceutical plants
What's Your Reaction?
.gif)